Importantly, inhibition of miR-199a ameliorated these abnormalities, supporting our hypothesis and highlighting the critical role of the MeCP2/miR-199a axis in MDS pathophysiology. This evidence concerns the gene MECP2 and myelodysplastic syndrome.